Scope
This NICE guideline (NG20) covers recognising, assessing and managing coeliac disease in children, young people and adults. It sets out who should be offered or considered for serological testing and why people need to keep eating gluten during diagnosis. It specifies first-line and IgA-deficiency antibody testing by age group and limits HLA typing to specialist use. It also covers referral for biopsy or paediatric specialist assessment, annual review and follow-up, the approach to non-responsive and refractory disease, and patient information, psychological wellbeing, pneumococcal immunisation, supplements and gluten-free oats.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Who to test
- Offer coeliac serology to people with any of these: persistent unexplained abdominal or gastrointestinal symptoms, faltering growth, prolonged fatigue, unexpected weight loss, severe or persistent mouth ulcers, or unexplained iron, vitamin B12 or folate deficiency. [1]
- Also offer serology at diagnosis of type 1 diabetes or autoimmune thyroid disease. Offer it to adults with irritable bowel syndrome and to first-degree relatives of people with coeliac disease. [1]
- Consider serology in people with any of these: metabolic bone disorder; unexplained neurological symptoms, particularly peripheral neuropathy or ataxia; unexplained subfertility or recurrent miscarriage; persistently raised liver enzymes of unknown cause; dental enamel defects; Down's syndrome; or Turner syndrome. [1]
Gluten intake before and during testing
- Explain that tests are accurate only if the person eats gluten throughout the diagnostic process. Advise people not to start a gluten-free diet until a specialist confirms the diagnosis, even after a positive serology result. People on a normal diet should eat gluten in more than 1 meal every day for at least 6 weeks before testing. [1]
- Some people have already restricted or excluded gluten and are reluctant or unable to reintroduce it before testing. Refer them to a gastrointestinal specialist and explain that biopsy confirmation may be difficult. [1]
- Do not offer serology to infants who have not yet had gluten introduced into their diet. [1]
Laboratory serological testing
- Serology should be done in CPA- or ISO15189-accredited laboratories. Total IgA should be measured with an assay specifically designed for that purpose. [1]
- In young people and adults, laboratories should test total IgA and IgA tTG as the first choice and use IgA EMA if IgA tTG is weakly positive. If IgA is deficient, they should consider IgG EMA, IgG DGP or IgG tTG. The guideline defines IgA deficiency as total IgA less than 0.07 g per litre. [1]
- In children, laboratories should test total IgA and IgA tTG first. If IgA is deficient, they should consider IgG EMA, IgG DGP or IgG tTG. [1]
- HLA DQ2/DQ8 typing should not be used for initial diagnosis in non-specialist settings. Specialists may consider it only in particular situations, such as children not having a biopsy, or people with limited gluten intake who decline a gluten challenge. [1]
Referral and follow-up after serology
- Refer young people and adults with positive serology to a gastrointestinal specialist for endoscopic intestinal biopsy to confirm or exclude coeliac disease. In this group, positive serology means unambiguously positive IgA tTG alone, or weakly positive IgA tTG plus positive IgA EMA. In IgA deficiency, any one positive IgG antibody counts as positive. [1]
- Refer children with positive serology to a paediatric gastroenterologist or a paediatrician with a gastroenterology interest. Further investigation may include, among other options, confirmatory IgA EMA, HLA genetic testing or endoscopic biopsy. [1]
- Refer people with negative serology to a gastrointestinal specialist if coeliac disease is still clinically suspected. Keep a low threshold for re-testing people in the offer or consider testing groups if they develop symptoms consistent with coeliac disease. [1]
- Advise people who test negative, particularly first-degree relatives and people with type 1 diabetes, that coeliac disease can present in many ways. They should consult a healthcare professional if any of the listed trigger symptoms arise or persist. [1]
Monitoring established disease
- Once continued gluten exposure has been excluded, consider referral for endoscopic biopsy in two situations. The first is serological titres that stay persistently high with little or no change after 12 months. The second is persistent symptoms such as diarrhoea, abdominal pain, weight loss, fatigue or unexplained anaemia. Serology alone should not be used to judge whether gluten has been excluded from the diet. [1]
- Offer an annual review that includes weight, height and symptom review. At that review, consider whether diet and gluten-free adherence need assessing and whether specialist dietetic or nutritional advice is needed. [1]
- If the annual review raises concerns, refer to a GP or consultant. They should assess the need for DEXA or active bone treatment, specific blood tests and specialist referral, and the risk of long-term complications and comorbidities. [1]
Non-responsive and refractory disease
- If symptoms persist despite advice to exclude gluten, consider three steps. Recheck the original diagnosis. Refer to a specialist dietitian to look for ongoing gluten exposure. Investigate complications or coexisting causes, such as irritable bowel syndrome, lactose intolerance, bacterial overgrowth, and microscopic or inflammatory colitis. [1]
- Diagnose refractory disease when the original diagnosis is confirmed and both gluten exposure and coexisting conditions have been excluded as causes of ongoing symptoms. Refer these patients to a specialist centre for further investigation. [1]
- For adults with refractory disease, prednisolone may be considered for initial symptom control while specialist advice is awaited. NICE's adrenal insufficiency guideline covers glucocorticoid withdrawal. [1]
Information, support and diet
- Tell people at risk that delayed or missed diagnosis can lead to continuing ill health and serious long-term complications. [1]
- After diagnosis, a professional with specialist coeliac knowledge should explain why a gluten-free diet matters and give information to help people follow it. This should cover gluten-containing foods and alternatives, food labelling, social situations and travel, and avoiding cross-contamination and accidental gluten intake when eating out. It should also cover the role of support groups. [1]
- Be alert to anxiety and depression in people with coeliac disease, and diagnose and manage these according to the relevant NICE guidelines. [1]
- Explain to people with coeliac disease, and to their family members or carers as appropriate, that the Department of Health's Green Book recommends pneumococcal immunisation. [1]
- Advise people with coeliac disease, and their family members or carers where appropriate, to check with their healthcare team before taking over-the-counter vitamin or mineral supplements. Explain to them that calcium or vitamin D supplements may be needed if dietary intake is insufficient. [1]
- Explain to people with coeliac disease, and their family members or carers where appropriate, that they can choose to include gluten-free oats at any stage. They will be advised whether to continue them based on their immunological, clinical or histological response. [1]
Limitations and use
- The summary covers only the clinical recommendations (sections 1.1–1.7 and the IgA deficiency definition). Research recommendations, rationale and update sections were not reviewed.
- Anxiety and depression management, DEXA assessment and glucocorticoid withdrawal are deferred to other NICE guidelines, which are not summarised here.
- No specific prednisolone dose or regimen is given; the source supports only considering it in adults while specialist advice is awaited.
- Any flowcharts or tables in the original document were not interpreted beyond the recommendation text.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Coeliac disease: recognition, assessment and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 2 September 2015
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.